Original document(55 pages)  中文版
    The invention relates to the modification of bryodin 1 to result in bryodin 1 proteins that are substantially nonimmunogenic or less immunogenic than any non-modified counterpart when used in vivo. The invention relates furthermore to T-cell epitope peptides derived from said nonmodified protein by means of which it is possible to create modified bryodin 1 variants with reduced immunogenicity.
Application Number
申请号		 03813443 Application Date
申请日		 2003.06.10
Title 名称 Modified byrodin 1 with reduced immunogenicity
Publication Number
公开号		 1658905 Publication Date
公开日		 2005.08.24
Approval Pub. Date Granted Pub. Date
International Classification 分类号 A61K47/48
Applicant(s) Name
申请人		 Merck Patent GmbH
Address 地址
Inventor(s) Name 发明人 Baker Matthew
Attorney & Agent 代理人 huang gesheng lin bainan

  
Mycoplasma polypeptides
Radiopharmaceutical formulations
Endotoxin-binding ligands and their use
Plasma sterilizer having dehumidifier
Polyurethane foam products with controlled release of agents and additives
Absorbent article containing a skincare composition
Gel materials, medical articles, and methods
Strontium-apatite-cement-preparations, cements formed therefrom, and uses thereof
Medical prosthetic devices having improved biocompatibility
Flow adaptive aspiration tubing and devices
Google
Note:All patent data come from State Intellectual Property Office of the People's Republic of China. If there were discrepancies between here and the State Intellectual Property office, the later is more accurate. The patent data is only for public exchange and learning purposes. We are not responsible for the adverse consequences with unverified use of the data.